Experienced in Neuroendocrine Tumor

Dr. Avi B. Markowitz

Oncology | Hematology
Utmb Faculty Group Practice
301 University Blvd, 
Galveston, TX 
Accepting New Patients
Experienced in Neuroendocrine Tumor
Utmb Faculty Group Practice
301 University Blvd, 
Galveston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Avi Markowitz is an Oncologist and a Hematologist in Galveston, Texas. Dr. Markowitz is rated as an Experienced provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Familial Colorectal Cancer, and Angiosarcoma. Dr. Markowitz is currently accepting new patients.

His clinical research consists of co-authoring 7 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in TX
Hospital Affiliations
University Of Texas Medical Branch Galveston
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

UTMB FACULTY GROUP PRACTICE
301 University Blvd, Galveston, TX 77555

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 1b Study of Berzosertib in Combination With Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
A Phase 1b Study of Berzosertib in Combination With Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2025
Intervention Type: Other, Radiation, Drug, Procedure
Study Drug: Berzosertib
Study Phase: Phase 1
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Veliparib
Study Phase: Phase 2
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination With Fulvestrant in Patients With Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor
A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination With Fulvestrant in Patients With Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor
Enrollment Status: Withdrawn
Publish Date: September 25, 2023
Intervention Type: Drug
Study Drugs: Copanlisib, Fulvestrant
Study Phase: Phase 1/Phase 2
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
View 6 Less Clinical Trials

7 Total Publications

Non-neoplastic inflammatory pseudotumor of the lung after immunotherapy for melanoma: A diagnostic pitfall on fine needle aspiration biopsy of lung.
Non-neoplastic inflammatory pseudotumor of the lung after immunotherapy for melanoma: A diagnostic pitfall on fine needle aspiration biopsy of lung.
Journal: Diagnostic cytopathology
Published: April 08, 2021
Similar Doctors
James C. Yao
Elite in Neuroendocrine Tumor
Dr. James C. Yao
Oncology
Elite in Neuroendocrine Tumor
Dr. James C. Yao
Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (46.8 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances

James Yao is an Oncologist in Houston, Texas. Dr. Yao is rated as an Elite provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Metastatic Insulinoma, Carcinoid Syndrome, and Pancreatectomy.

Elite in Neuroendocrine Tumor
Dr. Chandrikha Chandrasekharan
Oncology | Palliative Medicine
Elite in Neuroendocrine Tumor
Dr. Chandrikha Chandrasekharan
Oncology | Palliative Medicine

MD Anderson

1515 Holcombe Blvd, 
Houston, TX 
 (46.3 miles away)
713-792-2121
Languages Spoken:
English, Hindi, Tamil
See accepted insurances
Accepting New Patients
Offers Telehealth

Chandrikha Chandrasekharan is an Oncologist and a Palliative Medicine provider in Houston, Texas. Dr. Chandrasekharan is rated as a Distinguished provider by MediFind in the treatment of Neuroendocrine Tumor. Her top areas of expertise are Neuroendocrine Tumor, Pancreatic Cancer, Familial Pancreatic Cancer, and Carcinoid Syndrome. Dr. Chandrasekharan is currently accepting new patients.

Distinguished in Neuroendocrine Tumor
Dr. Nizar M. Tannir
Oncology | Urology
Distinguished in Neuroendocrine Tumor
Dr. Nizar M. Tannir
Oncology | Urology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (46.8 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances

Nizar Tannir is an Oncologist and an Urologist in Houston, Texas. Dr. Tannir is rated as an Elite provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Neuroendocrine Tumor, Nephrectomy, and Orchiectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Markowitz's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 74 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile